Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria

Stephan Ehrhardt, Christian G. Meyer

Research output: Contribution to journalReview articlepeer-review


The World Health Organization strongly recommends artemisinin-based combination therapy (ACT) regimens for the treatment of uncomplicated Plasmodium falciparum malaria cases in endemic areas. Among the combinations of compounds that are available at present, excellent results have been obtained for the artemisinin derivative artemether, in a combination galenic preparation with lumefantrine (artemether-lumefantrine, AL). Here, the pharmacological properties and the therapeutic options of both substances are briefly reviewed and a cursory overview is given on recent trials that have compared the therapeutic effects of AL in the standard 6-dose regimen with other antimalarials and combinations. In order to ensure the most achievable and reliable adherence and compliance of children in the treatment of malaria, a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance to ACT regimens in Asia, however, are alarming.

Original languageEnglish (US)
Pages (from-to)805-815
Number of pages11
JournalTherapeutics and Clinical Risk Management
Issue number1
StatePublished - 2009
Externally publishedYes


  • Artemether
  • Dispersible formulation
  • Lumefantrine
  • Malaria
  • Plasmodium falciparum
  • Therapy
  • Treatment

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety


Dive into the research topics of 'Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria'. Together they form a unique fingerprint.

Cite this